Newsroom

Download PDF BOSTON–(BUSINESS WIRE)–Aug. 30, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13Time: 7:00 a.m. Eastern Time Baird 2021 Global Healthcare ConferenceDate: Tuesday, September 14Time: 3:10 p.m. Eastern Time A live webcast of the Baird fireside chat can be accessed by

Download PDF – Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million – – Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021 – – COVID-19 Related Manufacturing Supply Shortages to Push Potential Registrational Study Start for Ficlatuzumab to 2023 – – Company to Host Conference

Download PDF BOSTON–(BUSINESS WIRE)–Jul. 29, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 5, 2021, to discuss the financial results and provide

Download PDF Webinar on Friday, July 16th at 12 p.m. Eastern Time FOTIVDA recently surpassed 300 total commercial prescriptions since its March 22, 2021 launch BOSTON–(BUSINESS WIRE)–Jul. 8, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib), AVEO’s oral, once-daily, differentiated vascular endothelial

Download PDF Webinar on Wednesday, June 16 at 2:00 p.m. Eastern Time BOSTON–(BUSINESS WIRE)–Jun. 7, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied

Download PDF BOSTON–(BUSINESS WIRE)–May 25, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF – Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX®) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab/Cetuximab Combination – – Phase 3 Go/No-Go Decision Expected After FDA Feedback – – Results to

Download PDF – Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up – – Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Compared to Sorafenib – – Data to be